Mesothelioma Market Outlook 2026-2036: Immunotherapy, AI-Driven Pipelines and Rising Momentum Across the 8MM | Thelansis

Mesothelioma is rare, but it is no longer a neglected cancer. After years with few options, the field is seeing real movement in immunotherapy, new targets and regulatory support. The market is moving from a chemotherapy-only past toward a mix of immunotherapy and novel mechanisms. The 2026 pipeline is more active than it has been in years.

Executive Summary
Mesothelioma, mainly malignant pleural mesothelioma (MPM), is an aggressive cancer linked to asbestos exposure, with a latency of 30 to 50 years. Estimated about 31,500 new cases and roughly 25,400 deaths worldwide, with Europe carrying nearly half of the burden. Many countries have banned asbestos, but because the disease appears decades after exposure, an ageing population keeps case numbers significant.

Thelansis has published two new reports to help decision-makers: Mesothelioma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036) and Mesothelioma Emerging Therapy, Unmet Needs & TPP Insights Report (2026).

Want the full picture? Explore the Mesothelioma Market Outlook and Forecast Report here: https://thelansis.com/reports/mesothelioma-market-outlook-forecast-2026-to-2036/

Key Emerging Players or Therapies
The pipeline spans immunotherapies, targeted agents, cell therapies and metabolic approaches.
• ISM6331 (Insilico Medicine): An AI-designed pan-TEAD inhibitor that received FDA Fast Track Designation in July 2026 for advanced mesothelioma. Phase I data have been accepted for presentation at ESMO 2026.
• Pegargiminase (Polaris Group): An arginine-depleting enzyme given with chemotherapy. It met its primary overall survival endpoint in the ATOMIC-Meso trial in non-epithelioid disease, and its BLA is under FDA review.
• Volrustomig (AstraZeneca): A PD-1/CTLA-4 bispecific being tested alongside chemotherapy in a Phase III study against chemotherapy or nivolumab plus ipilimumab in unresectable pleural mesothelioma.
• CAR-T, tumor-targeted agents and new combinations continue to enroll patients in Phase I-III studies.

See what KOLs expect from the next wave of therapies. Get the Emerging Therapy, Unmet Needs & TPP Insights Report here: https://thelansis.com/reports/mesothelioma-emerging-therapy-with-unmet-needs-and-tpp-insights/

Key Current Therapies or Standard of Care
For years, platinum plus pemetrexed was the standard first-line systemic option. That changed in 2020, when the FDA approved nivolumab plus ipilimumab, the first new regimen for mesothelioma in 16 years. Pembrolizumab combined with chemotherapy added a further first-line option in the US in September 2024.
• Nivolumab + ipilimumab is now a preferred option for non-epithelioid disease
• Chemo-immunotherapy gives epithelioid patients more choice
• Five-year CheckMate 743 data, published in March 2026, showed about 14% of patients on the immunotherapy combination alive at five years versus 6% on chemotherapy, a rare long-term signal in this disease
• Surgery and radiotherapy still play a role in carefully selected patients

Key Market Drivers and Trends
• Immunotherapy has reset expectations for survival and for what counts as a meaningful benefit
• Regulatory support, including orphan and fast-track designations, is speeding up development
• Targeted approaches such as TEAD inhibition and arginine depletion are widening the pipeline beyond checkpoint inhibitors
• Histology-based treatment selection (epithelioid vs non-epithelioid) is shaping trial design and pricing conversations
• Earlier and more accurate diagnosis remains a priority across the 8MM, including China, where treatment access is still evolving

Key Unmet Need and KOL Expectations
Despite progress, most patients still face a poor prognosis, and outcomes remain short of what other cancers now see.
• Epithelioid disease needs options that beat today's standards
• There are few effective choices after first-line therapy fails
• Biomarkers to guide treatment choice are limited
• Diagnosis often comes late, when options are narrower
Specialists tell a consistent story: they want durable survival gains, manageable safety and combinations that fit real-world patients, who are often older and frailer than trial participants.

TPP Insights
A winning mesothelioma therapy will probably need to show:
• Clear survival benefit over nivolumab plus ipilimumab or chemo-immunotherapy
• Strong activity in both epithelioid and non-epithelioid histologies
• A safety profile suitable for older patients
• Convenient dosing that fits routine oncology practice
• Evidence that supports reimbursement across diverse 8MM payer systems

Commercial Opportunity
Mesothelioma is a small patient population, but orphan incentives and a field still open to new mechanisms make it an attractive niche. Companies that match their products to unmet needs and plan early for regional access will be best placed to capture value through 2036.
• First movers in new mechanisms can build leadership while the field is still forming
• Combination strategies may open the door to wider use
• China and Japan offer growth potential alongside the US and Europe
• Partnering and licensing activity is likely to grow as late-stage data mature

Get Thelansis complete market forecast, competitive landscape and TPP insights report here:
• Mesothelioma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036): https://thelansis.com/reports/mesothelioma-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pr&utm_campaign=mes_mo

• Mesothelioma Emerging Therapy, Unmet Needs & TPP Insights Report (2026): https://thelansis.com/reports/mesothelioma-emerging-therapy-with-unmet-needs-and-tpp-insights/?utm_source=openpr&utm_medium=pr&utm_campaign=mes_tpp

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

This release was published on openPR.